mPOC(Molecular Point-of-Care) 시장 전망과 혁신 - 제11판(2025-2030년)

Molecular point-of-care testing continues to reshape diagnostic workflows by bringing the accuracy of molecular methods closer to the patient. In Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 11th Edition (2025 to 2030), Kalorama Information examines a market that has matured significantly over the past decade while remaining dynamic. Distinctions between true point-of-care and near patient molecular testing are not always clear, but Kalorama defines the core value of mPOC as smaller, portable diagnostic devices that answer workflows with rapid turnaround times that make molecular testing practical in physician offices and other decentralized settings.

What This Report Covers

This report provides a comprehensive assessment of the global molecular point-of-care market, with coverage that includes:

• Market estimates and forecasts for systems and consumables through 2030
• Segmentation by region, disease area, and company
• Analysis of both true molecular point-of-care systems and the broader near patient molecular market
• Market and product level revenue estimates supported by primary and secondary research

Research inputs include company disclosures, government publications, trade journals, business press, analyst reports, legal filings, and interviews with manufacturers, laboratories, and industry experts. All market values are expressed in current U.S. dollars and reflect base year sales for 2025.

How Kalorama Defines Molecular Point-of-Care

The report distinguishes between two primary market segments:

• True molecular point-of-care systems, characterized by small footprints, rapid turnaround times, and CLIA waived status or near term waiver potential
• Near patient molecular systems, which include larger or modular platforms that support moderate or high complexity testing in decentralized settings

Key Applications and Growth Opportunities

Historically, mPOC systems have been most successful in respiratory testing, a trend reinforced by COVID-19. While this segment remains price sensitive and competitive with immunoassays, the report identifies additional growth opportunities.

Recent approvals of rapid PCR and molecular home tests have further expanded the addressable market and reinforced the clinical relevance of mPOC technologies.

Table of Contents

Chapter 1: Executive Summary

• About Kalorama Information
• Scope and Methodology
• mPOC Market Overview
  • Defining True Molecular Point-of-Care
  • Defining Near-Patient Molecular POC
• Where Is Molecular Point-of-Care in 2026?
  • True mPOC Systems
    • Table 1-1: Global Molecular Point-of-Care Market, 2025-2030 ($ million)
  • "Near-Patient" Molecular Systems Market
    • Table 1-2: Global Near Patient Molecular Systems Market, 2025-2030 ($ million)
  • mPOC Market Observations and Trends
• Usage of Molecular Point-of-Care
• Leading mPOC Platforms
  • Table 1-3: Molecular POC Diagnostic Platforms and Technologies
• Trends

Chapter 2: Molecular Point-of-Care Market Development and Trends

• Molecular POC and COVID-19
  • Table 2-1: Molecular POC COVID-19 Tests and Regulatory Status
  • CDC Initial Response, Long Term Situation
  • COVID-19's Unique Challenge
  • BARDA Directs Funding to mPO
• Regulatory Developments
• Consortia, Funding, Prizes
• Deals
  • Table 2-2: Deals in Molecular Point-of-Care, April 2019-December 2025
• Advantages and Disadvantages of Molecular Point-of-Care
  • Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
• Justification: The Sensitivity/Specificity Argument
• New Systems and Menu Expansion
  • New Systems Introduced, in Development
  • Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
  • STI Continues to Be a Growth Area
• Deals, Investment in mPOC Systems
  • Roche's Supply and Manufacturing Agreement with Sapphiros
  • Cepheid's Partnership with Oxford Nanopore
  • Roche Acquires LumiraDx
  • Thermo Acquires Mesa Biotech
• China as a POC Market
• Common Tests and Analytes in POC Diagnostics
• Component Technologies of Molecular Point-of-Care Diagnostics
  • Microfluidics
  • Quantitative PCR (qPCR)
  • Microarrays
  • Isothermal Amplification
  • Test Automation
  • Primers and Probes
  • Detection
  • Molecular Diagnostics
  • Real-Time PCR (qPCR)
  • Isothermal Amplification Methods
  • Line Probe Assays
  • Next-Generation Sequencing
  • Applications and Potential Applications for Molecular Point-of-Care
  • Major Testing Areas for Molecular POC Diagnostics
  • Influenza
  • Reclassification of RIDTs
  • Hospital-Acquired Infections (HAIs)
  • Strep A
  • Respiratory Syncytial Virus (RSV)
  • Emerging Applications
  • Zika
  • Other Respiratory Infections
  • Group B Streptococcus
  • Human Papillomavirus
  • Herpes Simplex Virus
  • Vaginitis
  • Tuberculosis
  • Malaria
  • Other Tropical and Neglected Diseases
  • Cancer
• European Device Regulations

Chapter 3: mPOC Market Analysis

• Molecular Point-of-Care Market Analysis
  • Table 3-1: Global Molecular Point-of-Care Market, 2025-2030 ($ million)
  • Figure 3-1: Global Molecular Point-of-Care Market, 2025-2030 ($ million)
  • Market Assumptions and Conclusions
  • Regional Shares
    • Table 3-2: Geographic Breakout of the Molecular Point-of-Care (mPOC) Market, by Region, 2025 ($ million) [APAC, Europe, North America, Rest of World]
  • Segment Breakout
    • Figure 3-2: Global True mPOC Market, by Disease Indication, 2025 (%) [Respiratory, Other]
• "Near Patient Molecular" Market
  • Table 3-3: Global Near Patient Molecular Systems Market, 2025-2030 ($ million)
  • Figure 3-3: Global Near Patient Molecular Systems Market, 2025-2030 ($ million)
  • Figure 3-4: Global Near Patient mPOC Market Share, by Segment, 2025 (%) [Respiratory/COVID, STI/Women's Health, Other]
  • Figure 3-5: Global Respiratory Near Patient mPOC Market Share, by Test Type, 2025 (%) [Combo/Syndromic, Single Pathogen]
  • Market Share Near Patient
    • Figure 3-6: Near Patient Molecular Testing Market Share, by Vendor, 2025 (%)

Chapter 4: Company Profiles

• Abbott Laboratories
• Aidian Oy
• Akonni Biosystems
• binx health, inc.
• Biocartis NV
• bioMerieux SA
  • Table 4-1: FilmArray and SpotFire Est. Systems Installed per Quarter, Q4 2018-Q3 2025
  • Figure 4-1: FilmArray and SpotFire Est. Systems Installed by Quarter, Q4 2018-Q3 2025
  • Figure 4-2: bioMerieux Molecular Biology Revenues by Quarter, Q1 2016-Q3 2025
• Cepheid (Danaher)
  • Molecular Healthcare-Acquired Infection (HAI) Testing
  • Molecular Sexual Health and Women's Health Testing
  • Molecular Critical Infectious Disease Testing
  • Molecular Oncology/Genetics Testing
• Credo Diagnostics Biomedical Pte. Ltd.
• Curetis NV (OpGen)
• DiaSorin S.p.A
• GenMark Diagnostics (Roche)
• Greiner Bio-One GmbH
• Meridian Bioscience, Inc. (SD Biosensor)
• Mesa Biotech, Inc. (Thermo)
• Sherlock Biosciences
• QIAGEN NV
• QuantuMDx Group
• QuidelOrtho Corporation
• Roche
• Sekisui Diagnostics LLC